The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Open accessAbstract
The contribution of BRCA1 and BRCA2 to inherited breast cancer was assessed by linkage and mutation analysis in 237 families, each with at least four cases of breast cancer, collected by the Breast Cancer Linkage Consortium. Families were included without regard to the occurrence of ovarian or other cancers. Overall, disease was linked to BRCA1 in an estimated 52% of families, to BRCA2 in 32% of families, and to neither gene in 16% (95% confidence interval [CI] 6%-28%), suggesting other predisposition genes. The majority (81%) of the breast-ovarian cancer families were due to BRCA1, with most others (14%) due to BRCA2. Conversely, the majority of families with male and female breast cancer were due to BRCA2 (76%). The largest proportion (67%) of families due to other genes was found in families with four or five cases of female breast cancer only. These estimates were not substantially affected either by changing the assumed penetrance model for BRCA1 or by including or excluding BRCA1 mutation data. Among those families with disease due to BRCA1 that were tested by one of the standard screening methods, mutations were detected in the coding sequence or splice sites in an estimated 63% (95% CI 51%-77%). The estimated sensitivity was identical for direct sequencing and other techniques. The penetrance of BRCA2 was estimated by maximizing the LOD score in BRCA2-mutation families, over all possible penetrance functions. The estimated cumulative risk of breast cancer reached 28% (95% CI 9%-44%) by age 50 years and 84% (95% CI 43%-95%) by age 70 years. The corresponding ovarian cancer risks were 0.4% (95% CI 0%-1%) by age 50 years and 27% (95% CI 0%-47%) by age 70 years. The lifetime risk of breast cancer appears similar to the risk in BRCA1 carriers, but there was some suggestion of a lower risk in BRCA2 carriers <50 years of age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850 · cited 1×
“The risks conferred by BRCA1 have been estimated both from linkage data (Easton et al. 1995) and from the study of cancer incidence in carriers within families with disease believed to be linked to the gene (Ford et al. 1994).”
BackgroundSelf-citation
Research works printed but not linked: 38
- Bowcock, 1993, THRA1 and D17S183 flank an interval of <4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21, Am J Hum Genet, 52, 718
- Claus, 1991, Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study, Am J Hum Genet, 48, 232
- Claus, 1993, Analysis of the genetic relationship between breast and ovarian cancer, Am J Hum Genet, 787
- Cottingham, 1993, Faster sequential genetic linkage computations, Am J Hum Genet, 53, 252
- Easton, 1993, Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families, Am J Hum Genet, 52, 678
- Easton, 1995, Breast and ovarian cancer incidence in BRCA1-mutation carriers, Am J Hum Genet, 56, 265
- Easton, 1997, Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13, Am J Hum Genet, 61, 120, 10.1086/513891 · DOI · Paper page
- Elston, 1995, Twixt cup and lip: how intractable is the ascertainment problem?, Am J Hum Genet, 56, 15
- Ganguly, 1993, Confirmation sensitive gel electrophoresis for rapid detection of single base differences in double stranded PCR products and DNA fragments—evidence for solvent induced bends in DNA heteroduplexes, Proc Natl Acad Sci USA, 90, 10325, 10.1073/pnas.90.21.10325 · DOI · Paper page
- Gayther, 1996, Rpaid detection of regionally clustered germ-line BRCA1 mutations by multiple heteroduplex analysis, Am J Hum Genet, 58, 451
- Gayther, 1997, Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene, Nat Genet, 15, 103, 10.1038/ng0197-103 · DOI · Paper page
- Gayther, 1995, Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation, Nat Genet, 11, 428, 10.1038/ng1295-428 · DOI · Paper page
- Gyapay, 1994, The 1993–94 Généthon human genetic linkage map, Nat Genet, 7, 246, 10.1038/ng0694supp-246 · DOI · Paper page
- Håkansson, 1997, Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer, Am J Hum Genet, 60, 1068
- Hall, 1992, Closing in on a breast cancer gene on chromosome 17q, Am J Hum Genet, 50, 1235
- Hall, 1990, Linkage of early onset familial breast cancer to chromosome 17q21, Science, 250, 1684, 10.1126/science.2270482 · DOI · Paper page
- Hemmenki, 1997, Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis, Nat Genet, 15, 87, 10.1038/ng0197-87 · DOI · Paper page
- Hogervorst, 1995, Rapid detection of BRCA1 mutations by the protein truncation test, Nat Genet, 10, 208, 10.1038/ng0695-208 · DOI · Paper page
- Holt, 1996, Growth retardation and tumour inhibition, Nat Genet, 12, 298, 10.1038/ng0396-298 · DOI · Paper page
- Kerangueven, 1995, Loss of heterozygosity and linkage analysis in breast-carcinoma—indication for a putative 3rd susceptibility gene on the short arm of chromosome 8, Oncogene, 10, 1023
- Lathrop, 1984, Strategies for multilocus linkage analysis in humans, Proc Natl Acad Sci USA, 81, 3443, 10.1073/pnas.81.11.3443 · DOI · Paper page
- Liaw, 1997, Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome, Nat Genet, 16, 64, 10.1038/ng0597-64 · DOI · Paper page
- Miki, 1994, Isolation of BRCA1, the 17q-linked breast and ovarian cancer susceptibility gene, Science, 266, 66, 10.1126/science.7545954 · DOI · Paper page
- Narod, 1995, Genetic heterogeneity of breast-ovarian cancer revisited., Am J Hum Genet, 57, 957
- Narod, 1995, An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families, Am J Hum Genet, 56, 254
- Peelen, 1997, A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families, Am J Hum Genet, 60, 1041
- Phelan, 1996, Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families, Nat Genet, 13, 120, 10.1038/ng0596-120 · DOI · Paper page
- Schubert, 1997, BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2, Am J Hum Genet, 60, 1031
- Seitz, 1997, Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families, Oncogene, 14, 741, 10.1038/sj.onc.1200881 · DOI
- Serova, 1997, Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer–susceptibility genes?, Am J Hum Genet, 60, 486
- Stoppa-Lyonnet, 1997, BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic, Am J Hum Genet, 60, 1021
- Stratton, 1994, Familial male breast cancer is not linked to BRCA1, Nat Genet, 7, 103, 10.1038/ng0594-103 · DOI
- Struewing, 1997, The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Engl J Med, 336, 1401, 10.1056/NEJM199705153362001 · DOI · Paper page
- Tavtigian, 1996, The complete BRCA2 gene and mutations in 13q-linked kindreds, Nat Genet, 12, 333, 10.1038/ng0396-333 · DOI · Paper page
- Tulinius, 1992, Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer, Br Med J, 305, 855, 10.1136/bmj.305.6858.855 · DOI
- Weber, 1990, Dinucleotide repeat polymorphisms at the D17S250 and D17S261 loci, Nucleic Acids Res, 18, 464
- Wooster, 1995, Identification of the breast cancer susceptibility gene BRCA2, Nature, 378, 789, 10.1038/378789a0 · DOI · Paper page
- Wooster, 1994, Localisation of a breast cancer susceptibility gene (BRCA2) to chromosome 13q by genetic linkage analysis, Science, 265, 2088, 10.1126/science.8091231 · DOI · Paper page
Cited by
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Self-citationRisks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Self-citationZondervan, K. T., Becker, C. M., & Missmer, S. A. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810764 · Cited by 2,249
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
A breast cancer prediction model incorporating familial and personal risk factors
Tyrer, J., Duffy, S. W., & Cuzick, J. (2004) · Statistics in Medicine · doi:10.1002/sim.1668 · Cited by 1,345
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171
Self-citationThe CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Self-citationCancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Self-citationControl of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2
Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., Liu, X., Jasin, M., Couch, F. J., & Livingston, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.022 · Cited by 861
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Self-citationUbiquitin-Binding Protein RAP80 Mediates BRCA1-Dependent DNA Damage Response
Kim, H., Chen, J., & Yu, X. (2007) · Science · doi:10.1126/science.1139621 · Cited by 540
Jonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Powell, S. N., & Kachnic, L. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206678 · Cited by 364
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., Froster, U. G., Schlehe, B., Bechtold, A., Arnold, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9430 · Cited by 314
van Oostrom, I., Meijers-Heijboer, H., Lodder, L. N., Duivenvoorden, H. J., van Gool, A. R., Seynaeve, C., van der Meer, C. A., Klijn, J. G. M., van Geel, B. N., Burger, C. W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.100 · Cited by 281
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.120 · Cited by 232
Self-citationPrediction of pathogenic mutations in patients with early-onset breast cancer by family history
Lalloo, F., Varley, J., Ellis, D., Moran, A., O'Dair, L., Pharoah, P., & Evans, D. G. R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12856-5 · Cited by 202
Prodromal interventions for schizophrenia vulnerability: the risks of being “at risk”
Corcoran, C., Malaspina, D., & Hercher, L. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.021 · Cited by 183
Fuss, J. O., & Tainer, J. A. (2011) · DNA Repair · doi:10.1016/j.dnarep.2011.04.028 · Cited by 170
Heemskerk-Gerritsen, B. A. M., Brekelmans, C. T. M., Menke-Pluymers, M. B. E., van Geel, A. N., Tilanus-Linthorst, M. M. A., Bartels, C. C. M., Tan, M., Meijers-Heijboer, H. E. J., Klijn, J. G. M., & Seynaeve, C. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9449-x · Cited by 153
“09 Necrosis 11 (26) 4 (13) Bleeding 20 (48) 12 (39) Prosthesis luxation 2 (5) 0 (0) Poor arterial inflow 0 (0) 1 (3) Pneumothorax 1 (2) 0 (0) Late complications Surgery due to late complication No 11 (13) 7 (12) .”
InfluentialDe Nicolo, A., Tancredi, M., Lombardi, G., Flemma, C. C., Barbuti, S., Di Cristofano, C., Sobhian, B., Bevilacqua, G., Drapkin, R., & Caligo, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0087 · Cited by 91
Implications of genetic epidemiology for the prevention of substance use disorders
Merikangas, K. R., & Avenevoli, S. (2000) · Addictive Behaviors · doi:10.1016/s0306-4603(00)00129-5 · Cited by 110
Rajendran, B. K., & Deng, C.-X. (2017) · Oncotarget · doi:10.18632/oncotarget.17225 · Cited by 73
Looking different, feeling different: women’s reactions to risk-reducing breast and ovarian surgery
kConFab Psychosocial Group on behalf of the kConFab Investigators, Hallowell, N., Baylock, B., Heiniger, L., Butow, P. N., Patel, D., Meiser, B., Saunders, C., & Price, M. A. (2012) · Familial Cancer · doi:10.1007/s10689-011-9504-4 · Cited by 66
Evans, D. G. R., Moran, A., Hartley, R., Dawson, J., Bulman, B., Knox, F., Howell, A., & Lalloo, F. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605606 · Cited by 52
Survival and tumor characteristics of German hereditary breast cancer patients
Hamann, U., & Sinn, H.-P. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006350518190 · Cited by 48
Self-citationLee, J. M., Kopans, D. B., McMahon, P. M., Halpern, E. F., Ryan, P. D., Weinstein, M. C., & Gazelle, G. S. (2008) · Radiology · doi:10.1148/radiol.2463070224 · Cited by 45
Karppinen, S.-M., Erkko, H., Reini, K., Pospiech, H., Heikkinen, K., Rapakko, K., Syväoja, J. E., & Winqvist, R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.030 · Cited by 42
Vencken, P. M. L. H., Kriege, M., Hooning, M., Menke‐Pluymers, M. B., Heemskerk‐Gerritsen, B. A. M., van Doorn, L. C., Collée, M. M., Jager, A., van Montfort, C., Burger, C. W., et al. (2013) · Cancer · doi:10.1002/cncr.27839 · Cited by 40
Liang, J., Cade, B. E., He, K. Y., Wang, H., Lee, J., Sofer, T., Williams, S., Li, R., Chen, H., Gottlieb, D. J., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.10.002 · Cited by 21
Liu, T., Yu, J., Gao, Y., Ma, X., Jiang, S., Gu, Y., & Ming, W.-K. (2023) · Cancers · doi:10.3390/cancers16010103 · Cited by 21
Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?
Bresser, P. J. C., Van Gool, A. R., Seynaeve, C., Duivenvoorden, H. J., Niermeijer, M. F., van Geel, A. N., Menke, M., Klijn, J. G. M., & Tibben, A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm274 · Cited by 18
You-on-a-chip’ for precision medicine
Low, L. A., & Tagle, D. A. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1456333 · Cited by 18
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers
Nemati Shafaee, M., Goutsouliak, K., Lin, H., Bevers, T. B., Gutierrez-Barrera, A., Bondy, M., & Arun, B. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06688-z · Cited by 12
Metadata
- Authors
- Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., Sobol, H., Teare, M. D., Struewing, J., Arason, A., Scherneck, S., Peto, J., Rebbeck, T. R., Tonin, P., Neuhausen, S., Barkardottir, R., Eyfjord, J., Lynch, H., Ponder, B. A. J., Gayther, S. A., Birch, J. M., Lindblom, A., Stoppa-Lyonnet, D., Bignon, Y., Borg, A., Hamann, U., Haites, N., Scott, R. J., Maugard, C. M., Vasen, H., Seitz, S., Cannon-Albright, L. A., Schofield, A., & Zelada-Hedman, M.
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 1998-03
- Volume
- 62
- Issue
- 3
- Pages
- 676-689
- ISSN
- 0002-9297 (ISSN-L)
- OpenAlex
- W2103970959
- Cited by
- 3,037
- References
- 1
- FWCI
- 77.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3601 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.